Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Mark Joseph Truty

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3776-527X; OpenAlex author ID A5029404091, A5158626600. Sources: ClinicalTrials.gov.

Their work

Papers
71 (first author 5, last author 14)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
270
Papers, trials and grants by year

2012: 6 papers · 2013: none · 2014: 3 papers · 2015: 3 papers · 2016: 4 papers · 2017: 3 papers · 2018: 2 papers · 2019: 2 papers · 2020: 3 papers · 2021: 6 papers · 2022: 6 papers · 2023: 8 papers, 1 trial · 2024: 7 papers · 2025: 7 papers · 2026: 11 papers

Papers 50 of 71

  1. Enhanced Molecular Staging of Pancreatic Cancer Using Methylated DNA Markers in Peritoneal Lavage Fluid. Co-author DOI 10.1002/jso.70292↗
  2. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  3. Epigenetic context defines the transcriptional activity of canonical and noncanonical NF-κB signaling in pancreatic cancer. Co-author DOI 10.1038/s41420-026-03019-9↗
  4. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  5. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  6. KLF5 controls subtype-independent highly interactive enhancers in pancreatic cancer to regulate cell survival. Co-author DOI 10.1126/sciadv.aea2106↗
  7. Next-generation AI for visually occult pancreatic cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisabi… Co-author DOI 10.1136/gutjnl-2025-337266↗
  8. Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0823↗
  9. Spatial Configuration of Pancreatic Cancer Is Associated with Disease Recurrence after Neoadjuvant Therapy and Curative-Intent Resection. Co-author DOI 10.1158/1078-0432.ccr-25-4968↗
  10. Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter? Co-author DOI 10.6004/jnccn.2025.7097↗
  11. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  12. Financial Toxicity of Long-Term Survivors Who Underwent Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/jso.27871↗
  13. Contemporary Advances, Evidence, and Considerations in Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.semradonc.2025.07.007↗
  14. Therapeutic targeting of FOSL1 and RELA-dependent transcriptional mechanisms to suppress pancreatic cancer metastasis. Co-author DOI 10.1038/s41419-025-07810-x↗
  15. Outcomes of Visceral Arterial Interposition Graft Reconstruction for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006350↗
  16. Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase II pause release to modulate classical subtype identity in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-334374↗
  17. Long-Term Reoperation Rates Following Pancreatoduodenectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1177/00031348241304021↗
  18. Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study. Last author DOI 10.1245/s10434-025-17036-y↗
  19. Impact of proton pump inhibitors on pathologic response rates following fluoropyrimidine-based neoadjuvant chemotherapy in pancreatic cancer patients. Co-author DOI 10.1002/jso.27837↗
  20. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
  21. Early vs conventional onset pancreatic ductal adenocarcinoma: analysis of surgical and oncologic outcomes in patients undergoing curative intent resection. Co-author DOI 10.1016/j.hpb.2023.09.010↗
  22. Quality of Life and Gastrointestinal Symptoms in Long-term Survivors of Pancreatic Cancer Following Pancreatoduodenectomy. Co-author DOI 10.1097/sla.0000000000006053↗
  23. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  24. Baseline Characteristics and Use of Pretherapeutic 18 F-Fluorodeoxyglucose-PET for Pancreatic Cancer. Last author DOI 10.1097/xcs.0000000000001059↗
  25. Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma. Last author DOI 10.1245/s10434-023-14875-5↗
  26. Bounding box-based 3D AI model for user-guided volumetric segmentation of pancreatic ductal adenocarcinoma on standard-of-care CTs. Co-author DOI 10.1016/j.pan.2023.05.008↗
  27. In vivo label-free optical signatures of chemotherapy response in human pancreatic ductal adenocarcinoma patient-derived xenografts. Co-author DOI 10.1038/s42003-023-05368-y↗
  28. Yield of Staging Laparoscopy for Pancreatic Cancer in the Modern Era: Analysis of More than 1,000 Consecutive Patients. Last author DOI 10.1097/xcs.0000000000000704↗
  29. Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2022-328154↗
  30. Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-22-0916↗
  31. Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot St… Last author DOI 10.1245/s10434-022-12328-z↗
  32. Oncologic Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Highly Selected Patients with Metastatic Pancreatic Ductal Adenoc… Co-author DOI 10.1245/s10434-023-14138-3↗
  33. Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phas… Co-author DOI 10.1371/journal.pone.0294564↗
  34. 2021 SSAT Debate: Selective Approach to Resection of the Superior Mesenteric Artery in Pancreatic Cancer vs Superior Mesenteric Artery Encasement Is Not an Abs… First author DOI 10.1007/s11605-021-05237-1↗
  35. Pancreatic Cancer is More Frequently Early Stage at Diagnosis in Surgically Resected Intraductal Papillary Mucinous Neoplasms With Preoperative Surveillance. Co-author DOI 10.1016/j.gastha.2022.07.004↗
  36. Patency rates of hepatic arterial resection and revascularization in locally advanced pancreatic cancer. Last author DOI 10.1016/j.hpb.2022.06.005↗
  37. Patterns of Recurrence After Primary Local Therapy for Pancreatic Ductal Adenocarcinoma - A Critical Review of Rationale and Target Delineation for (Neo)Adjuva… Co-author DOI 10.1016/j.prro.2022.06.004↗
  38. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Last author DOI 10.1245/s10434-021-10991-2↗
  39. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Last author DOI 10.6004/jnccn.2022.7041↗
  40. Perception versus reality: A National Cohort Analysis of the surgery-first approach for resectable pancreatic cancer. Last author DOI 10.1002/cam4.4144↗
  41. Molecular Peritoneal Staging for Pancreatic Ductal Adenocarcinoma Using Mutant KRAS Droplet-Digital Polymerase Chain Reaction: Results of a Prospective Clinica… Last author DOI 10.1016/j.jamcollsurg.2021.05.009↗
  42. Commentary on: Periarterial divestment in pancreatic cancer surgery. Co-author DOI 10.1016/j.surg.2020.10.043↗
  43. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003284↗
  44. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and… Co-author DOI 10.2214/ajr.20.24567↗
  45. Tyrosine Phosphoproteomics of Patient-Derived Xenografts Reveals Ephrin Type-B Receptor 4 Tyrosine Kinase as a Therapeutic Target in Pancreatic Cancer. Co-author DOI 10.3390/cancers13143404↗
  46. En Bloc Celiac Axis Resection for Pancreatic Cancer: Classification of Anatomical Variants Based on Tumor Extent. Co-author DOI 10.1016/j.jamcollsurg.2020.05.005↗
  47. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Co-author DOI 10.1016/j.surg.2019.12.008↗
  48. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2020-0086↗
  49. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis. Co-author DOI 10.1002/jso.25681↗
  50. Successful Secondary Engraftment of Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma Patient-Derived Xenografts After Previous Failed Primary Engraftmen… Last author DOI 10.1016/j.tranon.2018.09.008↗

Trials 1

  1. "Answers in Hours" A Randomized Controlled Trial Using Microbiome Metagenomics for Bile Duct Cultures Principal investigator NCT05523154↗

Closest collaborators

The 25 strongest of 270 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael L. Kendrick · 29 shared papers, 2014–2026 · strength 4.19
  2. Cornelius A. Thiels · 17 shared papers, 2021–2026 · strength 3.34
  3. Sean Patrick Cleary · 18 shared papers, 2020–2026 · strength 2.85
  4. Susanne Gray Warner · 13 shared papers, 2022–2026 · strength 2.62
  5. Amro M. Abdelrahman · 14 shared papers, 2021–2026 · strength 2.45
  6. Jennifer A. Yonkus · 12 shared papers, 2021–2025 · strength 1.90
  7. Travis Edward Grotz · 11 shared papers, 2020–2026 · strength 1.72
  8. Roberto Alva‐Ruiz · 9 shared papers, 2021–2025 · strength 1.37
  9. Robert R. McWilliams · 8 shared papers, 2020–2026 · strength 1.27
  10. Steven A. Johnsen · 6 shared papers, 2023–2026 · strength 1.20
  11. Ajit Harishkumar Goenka · 7 shared papers, 2021–2026 · strength 1.13
  12. Jennifer L. Leiting · 7 shared papers, 2019–2026 · strength 1.06
  13. Rondell Patrell Graham · 8 shared papers, 2019–2023 · strength 0.95
  14. Chi Zhang · 4 shared papers, 2024–2025 · strength 0.89
  15. Andrea Zironda · 4 shared papers, 2024–2025 · strength 0.84
  16. Suresh T. Chari · 7 shared papers, 2015–2026 · strength 0.81
  17. Aashna Karbhari · 4 shared papers, 2023–2026 · strength 0.78
  18. Joana E. Aggrey-Fynn · 4 shared papers, 2023–2026 · strength 0.77
  19. Ryan Michael Carr · 3 shared papers, 2025–2026 · strength 0.76
  20. Zeynab Najafova · 4 shared papers, 2023–2026 · strength 0.69
  21. Thorvardur Ragnar Halfdanarson · 5 shared papers, 2021–2023 · strength 0.61
  22. Matthew H. G. Katz · 12 shared papers, 2012–2026 · strength 0.60
  23. Danielle Marie Carlson · 3 shared papers, 2024–2025 · strength 0.59
  24. Marina R. Walther-Antonio · 1 shared trial, 2023 · strength 0.58
  25. Ingmar Florin Rompen · 3 shared papers, 2026 · strength 0.57

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.